350-27-6

Basic information

• Product Name: 3-FLUORO-4-METHOXYPHENACYL BROMIDE
• Synonyms: 3-FLUORO-4-METHOXYPHENACYL BROMIDE;2-Bromo-3'-fluoro-4'-methoxyacetophenone, 2-Bromo-1-(3-fluoro-4-methoxyphenyl)ethan-1-one, 4-(Bromoacetyl)-2-fluoroanisole;2-Bromo-1-(3-fluoro-4-methoxyphenyl)ethanone
• CAS NO: 350-27-6
• Molecular Formula: C₉H₈BrFO₂
• Molecular Weight: 247.06
• Mol File: 350-27-6.mol
• Article Data: 10

Chemical Properties

• Melting Point: 71-74
• Appearance: /
• Storage Temp.: Keep Cold
• Sensitive: Lachrymatory
• CAS DataBase Reference: 3-FLUORO-4-METHOXYPHENACYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-FLUORO-4-METHOXYPHENACYL BROMIDE(350-27-6)
• EPA Substance Registry System: 3-FLUORO-4-METHOXYPHENACYL BROMIDE(350-27-6)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 350-27-6(Hazardous Substances Data)

Usage

General Description

3-Fluoro-4-methoxyphenacyl bromide, also known as FMOCB, is a chemical compound commonly used in the synthesis of various pharmaceuticals and organic compounds. It is a brominated derivative of phenacyl bromide, often utilized as a reagent in the protection and deprotection of amino acids in peptide synthesis. FMOCB is also employed in the preparation of novel bioactive molecules and as a key intermediate in the production of agrochemicals and pharmaceuticals. Its unique reactivity and functional group compatibility make it a valuable tool in organic synthesis, particularly in the field of medicinal chemistry and drug development. Additionally, FMOCB is an important building block for the creation of diverse chemical structures with potential applications in drug discovery and development.

Upstream product

• 321-28-8 1-fluoro-2-methoxybenzene 
• 455-91-4 1-(3-fluoro-4-methoxyphenyl)ethanone 
• 598-21-0 2-Bromoacetyl bromide 

Downstream Products

• 1764-96-1 [4-(3-fluoro-4-methoxy-phenyl)-thiazol-2-yl]-phenyl-amine 
• 186093-84-5 2-(3-Fluoro-4-methoxy-benzoyl)-benzofuran-5-carbaldehyde 
• 1246766-47-1 C₁₉H₁₁F₇N₂O₃S 
• 956027-75-1 tert-butyl (3R)-3-({4-[6-(4-fluoro-3-methoxyphenyl)imidazo[2,1-b][1,3]thiazol-5-yl]pyrimidin-2-yl}amino)piperidine-1-carboxylate 
• 956027-78-4 tert-butyl 4-({4-[6-(4-fluoro-3-methoxyphenyl)imidazo[2,1-b][1,3]thiazol-5-yl]pyrimidin-2-yl}amino)piperidine-1-carboxylate 
• 956027-74-0 3-(dimethylamino)-1-[6-(4-fluoro-3-methoxyphenyl)imidazo[2,1-b][1,3]thiazol-5-yl]prop-2-en-1-one 
• 956027-73-9 1-[6-(4-fluoro-3-methoxyphenyl)imidazo[2,1-b][1,3]thiazol-5-yl]ethanone 

Relevant articles and documents

SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES

The invention relates to substituted dihydropyrazolo pyrazine carboxamide derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.

Synthesis and bioevaluation of N,4-diaryl-1,3-thiazole-2-amines as tubulin inhibitors with potent antiproliferative activity

A series of N,4-diaryl-1,3-thiazole-2-amines containing three aromatic rings with an amino linker were designed and synthesized as tubulin inhibitors and evaluated for their antiproliferative activity in three human cancer cell lines. Most of the target compounds displayed moderate antiproliferative activity, and N-(2,4-dimethoxyphenyl)-4-(4-methoxyphenyl)-1,3-thiazol-2-amine (10s) was determined to be the most potent compound. Tubulin polymerization and immunostaining experiments revealed that 10s potently inhibited tubulin polymerization and disrupted tubulin microtubule dynamics in a manner similar to CA-4. Moreover, 10s effectively induced SGC-7901 cell cycle arrest at the G2/M phase in both concentrationand time-dependent manners. The molecular docking results revealed that 10s could bind to the colchicine binding site of tubulin.

DIAMINOTHIAZOLES

The present invention is directed to novel diaminothiazoles of formula These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment 6r control of breast, lung and colon and prostate tumors.